Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Jazz Pharmaceuticals PLC
Operating Income
Jazz Pharmaceuticals PLC
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Operating Income
$659.4m
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
Perrigo Company PLC
NYSE:PRGO
|
Operating Income
$284.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-8%
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Operating Income
-$137.8m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-11%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Operating Income
-$41.2m
|
CAGR 3-Years
-351%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Operating Income
€12.2m
|
CAGR 3-Years
61%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Ovoca Bio PLC
LSE:OVB
|
Operating Income
-€2.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
12%
|
See Also
What is Jazz Pharmaceuticals PLC's Operating Income?
Operating Income
659.4m
USD
Based on the financial report for Dec 31, 2023, Jazz Pharmaceuticals PLC's Operating Income amounts to 659.4m USD.
What is Jazz Pharmaceuticals PLC's Operating Income growth rate?
Operating Income CAGR 10Y
7%
Over the last year, the Operating Income growth was 505%. The average annual Operating Income growth rates for Jazz Pharmaceuticals PLC have been 9% over the past three years , and 7% over the past ten years .